Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression

被引:13
作者
Morishita, S
Arita, S
机构
[1] Kawasaki Med Sch, Dept Psychiat, Kurashiki, Okayama 7010192, Japan
[2] Kansai Med Sch, Dept Math, Hirakata, Osaka, Japan
关键词
fluvoxamine; paroxetine; milnacipran; onset; depression;
D O I
10.1002/hup.508
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Selective serotonin reuptake inhibitors (SSRIs) and dual serotonin and noradrenaline reuptake inhibitors (SNRIs) are the most commonly prescribed class of antidepressants, yet it is not known whether one is superior to another. Aims The purpose of this clinical practice was to compare the periods of onset of action of fluvoxamine, paroxetine and milnacipran. Methods A retrospective cohort analysis was carried out among out-patients with depression treated in the Department of Psychiatry, Kawasaki Medical School Hospital, Kurashiki, Japan, in 2000 and 2001. A total of 206 patients receiving fluvoxamine, paroxetine and milnacipran were identified. Results The cumulative percentage of responders receiving milnacipran reached over 80% after 4 weeks, but it did reach this level for fluvoxamine or paroxetine until after 6 weeks. Conclusions The differential period of onset of action should help guide clinicians in determining a suitable duration of antidepressants for depression. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:479 / 482
页数:4
相关论文
共 12 条
[1]   CONTROLLED COMPARISON OF MILNACIPRAN AND FLUOXETINE IN MAJOR DEPRESSION [J].
ANSSEAU, M ;
PAPART, P ;
TROISFONTAINES, B ;
BARTHOLOME, F ;
BATAILLE, M ;
CHARLES, G ;
SCHITTECATTE, M ;
DARIMONT, P ;
DEVOITILLE, JM ;
DEWILDE, J ;
DUFRASNE, M ;
GILSON, H ;
EVRARD, JL ;
DENAYER, A ;
KREMER, P ;
MERTENS, C ;
SERRE, C .
PSYCHOPHARMACOLOGY, 1994, 114 (01) :131-137
[2]   Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine [J].
Clere, G .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (03) :145-151
[3]  
FEIGHNER JP, 1994, J CLIN PSYCHIAT, V55, P62
[4]   Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study [J].
Fukuchi, T ;
Kanemoto, K .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (02) :53-58
[5]   A RATING SCALE FOR DEPRESSION [J].
HAMILTON, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1960, 23 (01) :56-62
[6]   A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients [J].
Kiev, A ;
Feiger, A .
JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (04) :146-152
[7]   Suitable dose and duration of fluvoxamine administration to treat depression [J].
Morishita, S ;
Arita, S .
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (02) :177-181
[8]  
Nelson JC, 1997, J CLIN PSYCHIAT, V58, P26
[9]  
PRIEN RF, 1991, ARCH GEN PSYCHIAT, V48, P796
[10]   Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability [J].
Puech, A ;
Montgomery, SA ;
Prost, JF ;
Solles, A ;
Briley, M .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (02) :99-108